Article
Sanofi looks to widen Dupixent use to treat 'smoker's lung' after second trial win
Rating:
0.0
Views:
51
Likes:
1
Library:
1
Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed significant benefits.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value